Individuals who were mildly symptomatic following infection with SARS-CoV-2 B.1.1.28 have neutralizing antibodies to the P.1 variant
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Objectives
To evaluate if antibodies induced by infection with a different SARS-CoV-2 virus strain neutralize the P.1 variant.
Methods
Convalescent sera from 60 individuals following a documented SARS-CoV-2 infection were assayed for neutralizing antibody titer against both strains.
Results
Fifty-six and 50 sera were positive for neutralizing antibodies against the ancestral and P.1 strains, respectively. Neutralization titers were higher against the ancestral strain, but in the majority of patients differences did not differ by more than a single dilution.
Conclusions
Neutralizing antibodies that were generated following infection with SARS-CoV-2 B.1.1.28 were effective in vitro , against the SARS-CoV-2 P.1. variant.
Article activity feed
-
SciScore for 10.1101/2021.05.11.21256908: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: After explaining the study and obtaining written informed consent, peripheral blood was collected from each participant at one week intervals for 5 consecutive weeks (days 1, 7, 14, 21, 28) beginning up to 72 hours from the time of initial diagnosis. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources Vero cells were seeded in a 96-well microtiter plate and allowed to grow for 24 hours prior to infection. Verosuggested: NoneSoftware and Algorithms Sentences Resources Database management and statistical analysis were … SciScore for 10.1101/2021.05.11.21256908: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: After explaining the study and obtaining written informed consent, peripheral blood was collected from each participant at one week intervals for 5 consecutive weeks (days 1, 7, 14, 21, 28) beginning up to 72 hours from the time of initial diagnosis. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources Vero cells were seeded in a 96-well microtiter plate and allowed to grow for 24 hours prior to infection. Verosuggested: NoneSoftware and Algorithms Sentences Resources Database management and statistical analysis were performed using the Stata-15 software (Statacorp, College Station, Texas, USA). Statacorpsuggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:It is important to acknowledge limitations of our study. First, our cohort included a relatively small number of patients, all of whom recovered from mild or moderate episodes of COVID-19. It would be of interest to expand the study to determine if individuals with more severe disease differed in the occurrence or titer of antibodies cross-reactive to P.1. Secondly, our study only assessed neutralizing antibody titers for the first six weeks after initial infection. The length of time that the neutralizing antibody titers to the initiating strain and to the P.1 variant are maintained remains to be determined. Extending this study to later time points would be valuable to gain this additional information. Data on humoral immunity to other human coronaviruses have indicated that antibody levels wane over time2. A few studies have assessed antibody titers to MERS CoV and SARS CoV in the months and years following primary infection. Although limited in size these studies indicated that total binding antibodies and neutralizing antibodies progressively decreased such that by 2–3 years all infected individuals had minimal detectable antibody responses. There are reports of reinfection with homologous coronaviruses after as little as 80 days2. Thirdly, we did not measure other components of the immune response, such as cell-mediated immunity, which would further contribute to viral neutralization in vivo. It is likely that large prospective epidemiologic studies will be required to ...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
